<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prognosis of medulloblastoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prognosis of medulloblastoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prognosis of medulloblastoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jason Fangusaro, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amar Gajjar, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3180914">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medulloblastoma is the most common malignant brain tumor of childhood and occurs in the posterior fossa, predominantly in the cerebellum. Treatment consists of a combined-modality approach that includes surgery, radiation therapy (RT), and chemotherapy in most patients. Long-term survival is now achieved in approximately three-quarters of all patients with medulloblastoma, though specific risk groups have varied survival outcomes. Unfortunately, each component of therapy can cause delayed complications that have a profound effect on quality of life in survivors. Clinical trials and future research efforts are focused on attempts to decrease treatment toxicity while maintaining high cure rates in patients with medulloblastoma.
        </p>
        <p>
         The treatment and prognosis of medulloblastoma in children and adults, as well as the delayed complications of therapy, are discussed here. The clinical presentation, diagnosis, risk stratification, histopathology, and molecular pathogenesis of medulloblastoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5219.html" rel="external">
          "Clinical presentation, diagnosis, and risk stratification of medulloblastoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3177271">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal initial treatment of patients with medulloblastoma includes both general measures to alleviate increased intracranial pressure and specific therapy directed against the tumor. Based upon results from multiple cooperative group trials, the preferred approach in most patients includes a combination of maximal safe surgical resection, radiation therapy (RT) to both the tumor site and the craniospinal axis, and systemic chemotherapy. The application of this combined-modality approach to different risk groups is discussed below. (See
         <a class="local">
          'Initial therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3177278">
         <span class="h2">
          Increased intracranial pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with medulloblastoma often present with increased intracranial pressure due to obstructive hydrocephalus from compression of the fourth ventricle by the expanding tumor. Placement of a cerebrospinal fluid (CSF) shunt to relieve hydrocephalus is usually deferred until after a surgical resection, if it's performed at all, since surgery alone is often sufficient to treat this complication.
        </p>
        <p>
         Local swelling from the tumor can contribute to symptoms of increased intracranial pressure. This vasogenic tumor edema is typically temporarily relieved by treatment with glucocorticoids. The management of increased intracranial pressure is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6077.html" rel="external">
          "Elevated intracranial pressure (ICP) in children: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3177285">
         <span class="h2">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maximal safe resection is a key component of the treatment of all patients with medulloblastoma. Resection confirms the diagnosis, relieves increased intracranial pressure, and assists in local control. Surgery is used to remove as much of the tumor as possible without causing serious neurologic sequelae (eg, persistent ataxia, cranial nerve deficits).
        </p>
        <p>
         With modern surgical techniques and imaging guidance in the operating room, gross total or near-total resection is achieved in the majority of patients. Because of the potential for neurologic complications, however, total or radical resection is not always possible, and overly aggressive attempts to achieve complete resection should be avoided.
        </p>
        <p>
         Whether gross total resection confers improved survival over near-total resection has not been tested in a randomized trial. Observational data, mostly in the era before institution of combined craniospinal radiation and multiagent chemotherapy, have suggested that extent of resection is a key prognostic factor [
         <a href="#rid1">
          1-5
         </a>
         ]. However, the magnitude of this effect may be lower than previously thought, particularly when molecular group is taken into account [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         Surgical resection of tumors in the midline cerebellum can be associated with posterior fossa syndrome, also called cerebellar mutism, which occurs in approximately one-quarter of patients undergoing resection of a medulloblastoma. (See
         <a class="local">
          'Posterior fossa syndrome'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3177292">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         RT is an integral component of the initial management of patients with medulloblastoma. RT is used to control residual posterior fossa disease, to treat any disease that has spread along the craniospinal axis, and to prevent recurrence along the craniospinal axis. However, toxicity to the brain and spinal cord limits the doses used. This is particularly true in very young children, for whom craniospinal radiation is avoided or delayed due to severe toxicity to the rapidly developing central nervous system (CNS).
        </p>
        <p class="headingAnchor" id="H3177299">
         <span class="h3">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         After surgical excision, depending on the age of the child, medulloblastoma is treated with external beam RT to the craniospinal axis, with an additional boost to the primary tumor site [
         <a href="#rid4">
          4,8,9
         </a>
         ]. Contemporary radiation doses vary according to risk group. (See
         <a class="local">
          'Risk stratification'
         </a>
         below.)
        </p>
        <p>
         Contemporary RT techniques including proton RT and intensity-modulated RT (IMRT) are prioritized to limit radiation to normal tissues [
         <a href="#rid10">
          10-14
         </a>
         ]. While whole brain radiation with protons is no safer than with photons, use of protons or IMRT planning for primary site boost and spine RT avoids or minimizes radiation to the medial temporal lobes, inner ear, thyroid gland, lungs, heart, and adjacent abdominal organs compared with older techniques, without sacrificing disease control [
         <a href="#rid10">
          10,11,13-19
         </a>
         ].
        </p>
        <p>
         For average-risk disease in children (≥3 years of age), the whole brain and spine are typically treated with 23.4 Gy, with primary site boost of 30.6 Gy to a total dose of 54 Gy. For advanced-stage disease, 36 Gy is administered to the whole brain and spine, with a primary site boost of 18 Gy to a total dose of 54 Gy.
        </p>
        <p>
         The rationale for additional radiation (boost) to the tumor bed is based upon the observation that 50 to 70 percent of recurrences occur in the posterior fossa [
         <a href="#rid20">
          20,21
         </a>
         ]. The field of the boost includes the tumor bed and its margins (referred to as primary site or involved field boost). Compared with a full posterior fossa boost, use of an involved field boost reduces excess radiation exposure to normal brain and retains full treatment efficacy [
         <a href="#rid22">
          22
         </a>
         ]. Local failure in the posterior fossa outside the tumor bed is rare as the solitary site of failure [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         Using conventional techniques, the brain and spine are treated with separate but abutting RT fields. Placement of the junction between these two fields must be done precisely. Adjusting the site where these two fields abut each other two or three times during the course of craniospinal RT is routinely done to minimize the potential of overlapping dose to the spinal cord. However, sparing the spinal cord increases the dose to the thyroid gland, mandible, pharynx, and larynx. In developing children, this may increase the risk of late hypothyroidism or mandibular hypoplasia [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3177306">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although higher doses of RT are associated with better tumor control [
         <a href="#rid4">
          4,24
         </a>
         ], irradiation to the craniospinal axis in children is associated with a significant incidence of neurologic complications, including neurocognitive impairment. Whenever possible, RT is delayed for children younger than three years of age to permit further development of the CNS. (See
         <a class="local">
          'Neurocognitive impairment'
         </a>
         below.)
        </p>
        <p>
         In addition to its effects on neurocognitive development, craniospinal RT can cause decreased skeletal growth, hypothyroidism, adrenal insufficiency, and hypogonadism, all of which may be minimized with lower doses of radiation and/or newer techniques. (See
         <a class="local">
          'Complications of treatment'
         </a>
         below.)
        </p>
        <p>
         Because of the risks of serious complications, the initial management of pediatric patients with medulloblastoma has utilized adjuvant chemotherapy with decreased doses of RT in average-risk children or substituted chemotherapy for RT in the initial management of infants and young children. (See
         <a class="local">
          'Average-risk disease in children ≥3 years of age'
         </a>
         below and
         <a class="local">
          'Infants and young children'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3177313">
         <span class="h2">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemotherapy has an important role in the multimodality management of children with medulloblastoma in several settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In young children, chemotherapy is used after surgery to delay or avoid irradiating the developing brain and spinal cord. (See
         <a class="local">
          'Infants and young children'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In average-risk children, adjuvant chemotherapy is used following surgery and RT to decrease the incidence of recurrence and minimize craniospinal radiation exposure. (See
         <a class="local">
          'Average-risk disease in children ≥3 years of age'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chemotherapy is used with RT to treat high-risk disease. (See
         <a class="local">
          'High-risk disease in children ≥3 years of age'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3177320">
         <span class="h1">
          INITIAL THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H2952358">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combined-modality approach to the treatment of children with medulloblastoma has evolved in a stepwise fashion. Prior to use of radiation, no children survived with surgical resection alone as therapy. Radiation therapy (RT) was incorporated to reduce the rate of local recurrence in the surgical bed and along the craniospinal axis. (See
         <a class="local">
          'Radiation therapy'
         </a>
         above.)
        </p>
        <p>
         Most often, children with medulloblastoma are treated as part of a multicenter clinical trial or institution-specific protocol. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=88801" target="_blank">
          ClinicalTrials.gov
         </a>
         database maintained by the United States National Library of Medicine.
        </p>
        <p class="headingAnchor" id="H2952365">
         <span class="h3">
          Risk stratification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The current approach to the treatment of children with medulloblastoma varies according to two main factors: risk for recurrence, which depends primarily on extent of disease, and risk for treatment toxicity, with children younger than the age of three being at particularly high risk for neurologic impairment from RT. Using these factors, patients are divided into the following treatment groups  (
         <a class="graphic graphic_algorithm graphicRef129367" href="/z/d/graphic/129367.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infants and children younger than three years of age, who are at high risk of severe neurologic toxicity from craniospinal RT (see
         <a class="local">
          'Infants and young children'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children ≥3 years of age with average-risk disease, defined as total or near-total resection at the time of surgery, no evidence of disseminated disease by brain and spine magnetic resonance imaging (MRI) and lumbar cerebrospinal fluid (CSF) analysis, and classic or nodular desmoplastic histology (see
         <a class="local">
          'Average-risk disease in children ≥3 years of age'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children ≥3 years of age with high-risk disease, defined as the presence of ≥1.5 cm
         <sup>
          2
         </sup>
         of residual tumor after surgery, evidence of disseminated or metastatic disease, or large cell/anaplastic histology (see
         <a class="local">
          'High-risk disease in children ≥3 years of age'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         In addition to these factors, there is an increasing understanding that medulloblastomas are genetically heterogeneous and can be divided into at least four molecular groups, each with divergent genetics, clinical behavior, prognosis, and potentially therapeutic targets  (
         <a class="graphic graphic_table graphicRef109467" href="/z/d/graphic/109467.html" rel="external">
          table 1
         </a>
         ). These groups are being integrated into clinical trial design and will likely form the basis for improved risk stratification and individualized therapy in the future. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Molecular groups'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1675233504">
         <span class="h3">
          Infants and young children
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recommended approach for infants and young children consists of multiagent chemotherapy, often paired with autologous hematopoietic stem cell rescue, as part of a clinical trial protocol. The goal of chemotherapy is to delay or obviate the need for RT, and thereby allow the nervous system an opportunity to develop further, while maximizing survival outcomes [
         <a href="#rid25">
          25-34
         </a>
         ]. Use of craniospinal RT in this population results in unacceptably high rates of severe neurologic impairment in survivors. (See
         <a class="local">
          'Neurocognitive impairment'
         </a>
         below.)
        </p>
        <p>
         Molecular groups increasingly inform clinical trial design and interpretation of clinical trial results in infants. Cross-trial comparisons remain difficult due to small numbers of patients and heterogeneity of treatment regimens. Within these limitations, three major groups are emerging from the contemporary data in infants:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sonic hedgehog (SHH)
         </strong>
         – SHH pathway tumors make up approximately 75 percent of infant medulloblastomas. This group is largely overlapping with desmoplastic/nodular and extensive nodularity histologic variants. In these patients, the HIT-2000 trial regimen of multiagent systemic chemotherapy plus intraventricular
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and risk-adapted local RT resulted in excellent five-year progression-free and overall survival of 93 and 100 percent, respectively [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further analysis dividing infantile SHH tumors into two groups by deoxyribonucleic acid (DNA) methylation profiling indicates that the HIT-2000 regimen may be particularly effective in SHH-I tumors, which appear to have worse outcomes with regimens that do not include intraventricular chemotherapy [
         <a href="#rid36">
          36-38
         </a>
         ]. Across several trials, patients with SHH-II tumors have had excellent outcomes with chemotherapy-only regimens with or without intraventricular
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid35">
          35-37,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Group 3 and 4
         </strong>
         – Group 3 and 4 tumors make up the remaining 25 percent of medulloblastomas in infants. These groups have worse outcomes compared with SHH tumors. For group 3 in particular, the five-year survival with chemotherapy remains less than 50 percent [
         <a href="#rid35">
          35,36,40
         </a>
         ]. There appears to be no benefit to the inclusion of focal RT [
         <a href="#rid36">
          36
         </a>
         ]. Future trials in these groups will attempt to improve upon results of systemic chemotherapy with the possible addition of pre-relapse reduced-dose craniospinal RT and/or novel agents [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3177327">
         <span class="h3">
          Average-risk disease in children ≥3 years of age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to children age ≥3 years with medulloblastoma that is amenable to total or near-total resection includes surgery followed by craniospinal RT (23.4 Gy) with involved field boost (32.4 Gy), followed by adjuvant multiagent chemotherapy.
        </p>
        <p>
         The results of this approach in this patient subset are illustrated by the Children's Oncology Group (COG) ACNS0331 trial, which enrolled 549 patients ages 3 to 21 years with average-risk medulloblastoma from 2004 to 2014 [
         <a href="#rid22">
          22
         </a>
         ]. The trial was designed with a two-stage randomization to investigate two aspects of the RT portion of treatment: first, involved field versus (standard) posterior fossa RT boost in all patients; and second, reduced-dose (18 Gy) versus standard-dose (23.4 Gy) craniospinal RT in patients three to seven years of age. All patients received weekly
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         during RT, and maintenance chemotherapy consisted of alternating regimens of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         , and vincristine (cycle A) and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and vincristine (cycle B) with a cycle schedule of AABAABAAB. Of note, weekly vincristine during craniospinal RT is no longer considered universally standard for medulloblastoma, based on results of a separate trial [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         For the entire cohort of 464 eligible and evaluable children enrolled on COG ACNS0331 and with a median follow-up of 9.3 years, the five-year event-free and overall survival rates were 81 and 85 percent, respectively [
         <a href="#rid22">
          22
         </a>
         ]. An involved field RT boost resulted in similar outcomes compared with standard posterior fossa boost for both event-free survival (hazard ratio [HR] 0.97, one-sided 94% upper CI 1.35; five-year rates, 82.5 versus 80.5 percent) and overall survival (five-year rates, 84.6 versus 85.2 percent). No posterior fossa failures occurred outside the limited boost volume among children who received an involved field boost. Although it was hypothesized that narrowing the RT boost volume would lower certain toxicities, ototoxicity rates were similar between the two groups, and there were few significant differences in neurocognitive outcomes based on RT boost assignment. However, longer follow-up or a larger sample size may be needed to detect the benefit of reduced RT exposure upon neurocognitive and hearing outcomes.
        </p>
        <p>
         For the second randomization of craniospinal dose in children three to seven years of age, the reduced (18 Gy) dose of craniospinal RT resulted in worse outcomes compared with standard dose for both event-free survival (HR 1.67, one-sided 80% CI 2.10; five-year rates, 71.4 versus 82.9 percent, p = 0.28) and overall survival (five-year rates, 77.5 versus 85.6 percent, p = 0.049) [
         <a href="#rid22">
          22
         </a>
         ]. Post hoc segregation of patients into molecular groups demonstrated that the increased failure rate was limited to group 4 tumors and not to tumors of the Wingless-related integration site (Wnt) subgroup.
        </p>
        <p>
         Clinical trials in progress have adopted a reduced craniospinal RT dose for Wnt subgroup tumors, in the range of 15 to 18 Gy. For the other standard-risk tumors in this age group outside of a clinical trial, 23.4 Gy of craniospinal RT remains the standard of care based on the inferior survival outcomes associated with reduced-dose or deferred craniospinal RT [
         <a href="#rid22">
          22,42,43
         </a>
         ].
        </p>
        <p>
         Multidrug maintenance chemotherapy after RT is also standard of care. In both COG phase III trials that have incorporated multidrug maintenance chemotherapy after completion of RT in average-risk patients [
         <a href="#rid22">
          22,44
         </a>
         ], outcomes have been superior to those previously seen in trials using RT alone, even when a higher dose of RT was used [
         <a href="#rid9">
          9,24
         </a>
         ]. Results are also at least as good as those seen in trials using more intensive chemotherapy regimens [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
         Toxicities observed in the COG trials of craniospinal RT plus multiagent chemotherapy in average-risk disease have included the following [
         <a href="#rid22">
          22,47-49
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute grade 3 or 4 hematologic toxicity occurred in virtually all patients during treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe ototoxicity was seen in approximately 25 percent of patients. In a secondary analysis of one of the trials, cumulative
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         dose was not associated with event-free or overall survival, suggesting that lower doses of cisplatin can likely be used to help reduce ototoxicity without compromising survival outcomes [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant neurologic sequelae from surgery and RT occurred in approximately 25 percent of patients and persisted at one year in approximately one-half [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary malignancies occurred at a rate of 4.2 percent at 10 years [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Secondary neoplasms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurocognitive assessments in ACNS0331 showed worsening intelligence quotient (IQ) and processing speed scores over time, particularly in younger children [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detailed evaluation of endocrine outcomes has not been reported, but a significant frequency of such abnormalities is anticipated as seen historically.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3177334">
         <span class="h3">
          High-risk disease in children ≥3 years of age
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment for children with metastatic, unresectable, or anaplastic/large cell histology medulloblastoma is unknown, and there is an increased risk for recurrence and death even with multimodal treatment that includes RT and chemotherapy.
        </p>
        <p>
         Several prospective studies have examined adding concurrent chemotherapy to RT in an attempt to improve outcomes [
         <a href="#rid50">
          50-52
         </a>
         ]. However, accumulating data suggest that the use of concurrent chemotherapy during RT only increases toxicity, without meaningful survival benefit in most subgroups. The standard of care has therefore shifted to omit chemotherapy, including weekly
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , during delivery of craniospinal RT for medulloblastoma [
         <a href="#rid41">
          41
         </a>
         ]. Post-RT multiagent chemotherapy remains standard, and the doses of RT used for high-risk disease (36 Gy craniospinal RT plus 18 Gy primary site boost) are higher compared with average-risk disease.
        </p>
        <p>
         As an example, the COG ACNS0332 trial randomly assigned 294 children age 3 to 18 years with high-risk medulloblastoma (72 percent with metastatic disease) to receive craniospinal RT (36 Gy) and weekly
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         with or without daily
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         , followed by six cycles of maintenance chemotherapy with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and vincristine [
         <a href="#rid53">
          53
         </a>
         ]. A second randomization to examine
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         maintenance therapy closed early due to futility. With a median follow-up of 6.7 years and 261 patients evaluable, the addition of carboplatin to RT and vincristine did not significantly improve five-year event-free survival (66.4 versus 59.2 percent, p = 0.11) or overall survival (77.6 versus 68.8 percent, p = 0.28) for the entire cohort enrolled. Hematologic toxicity was greater with carboplatin during RT as well as during the first cycles of maintenance chemotherapy. Ototoxicity and neurocognitive toxicity were similar between groups.
        </p>
        <p>
         In a subgroup analysis of ACNS0332 according to molecular group, however, group 3 tumors (n = 79) appeared to benefit from concurrent
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         , with improved five-year event-free survival (73.2 versus 53.7 percent, p = 0.047) and a trend towards improved overall survival (82.8 versus 63.7 percent, p = 0.06) [
         <a href="#rid53">
          53
         </a>
         ]. However, these results require prospective confirmation.
        </p>
        <p>
         High-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) following RT has been explored in this group of patients. In a prospective study that included 48 patients with high-risk disease treated with craniospinal RT (36 to 39.6 Gy) followed by four cycles of high-dose chemotherapy and autologous HCT, the five-year event-free survival rate was 70 percent with no treatment-related mortalities [
         <a href="#rid54">
          54
         </a>
         ]. A subsequent prospective study using a more intensive chemotherapy regimen but with reduced-dose craniospinal RT (23.4 to 30.6 Gy) reported five-year event-free and overall survival rates of 70 and 74 percent, respectively, and a treatment-related mortality rate of 10 percent [
         <a href="#rid55">
          55
         </a>
         ]. Larger studies and long-term follow-up are needed to determine whether the additional short- and long-term risks of high-dose chemotherapy and autologous HCT regimens outweigh the potential benefits in this patient population.
        </p>
        <p>
         Another treatment modification being explored in patients with high-risk disease is hyperfractionated accelerated RT, which in at least two prospective studies appears to be feasible when combined with multidrug chemotherapy [
         <a href="#rid51">
          51,56
         </a>
         ]. The effect upon survival of this modality has yet to be determined.
        </p>
        <p class="headingAnchor" id="H3177348">
         <span class="h2">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medulloblastoma is rare in adults, and there are no randomized studies upon which to base treatment decisions, particularly in regard to the role of chemotherapy. The treatment approach  (
         <a class="graphic graphic_algorithm graphicRef129366" href="/z/d/graphic/129366.html" rel="external">
          algorithm 2
         </a>
         ) is informed primarily by indirect evidence in children and lower-quality evidence in adults.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery and risk stratification
         </strong>
         – As in children, maximal safe resection is recommended, and a postoperative brain MRI should be obtained within 48 hours of surgery to assess for residual disease. Staging includes a spine MRI with contrast and lumbar CSF cytology, which should be obtained either preoperatively, if safe, or two to three weeks postoperatively to maximize specificity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In adults, average risk is generally defined as having residual tumor &lt;1.5
         <sup>
         </sup>
         cm
         <sup>
          2
         </sup>
         , negative spine MRI, negative lumbar CSF cytology, and classic or desmoplastic histology. High-risk disease includes patients with bulky residual disease (&gt;1.5 cm
         <sup>
          2
         </sup>
         ), evidence of leptomeningeal dissemination or distant metastasis (either on brain and spine MRI or as seen on lumbar CSF cytology), and large cell/anaplastic histology [
         <a href="#rid57">
          57
         </a>
         ]. Molecular markers of high risk include group 4 (
         <em>
          MYC
         </em>
         amplification) and SHH tumors with mutant tumor protein p53 (
         <em>
          TP53
         </em>
         )
         <em>
         </em>
         [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Average-risk adults
         </strong>
         – For most average-risk adults, we suggest standard-dose craniospinal RT with primary site boost (ie, 30 to 36 Gy to neuraxis and a total of 54 Gy to the tumor bed plus a margin) followed by multiagent adjuvant chemotherapy. Standard-dose craniospinal RT alone, without adjuvant chemotherapy, is another alternative to combination therapy in older adults and those with poor functional status who may be unable to tolerate chemotherapy safely. Reduced-dose craniospinal RT (ie, 23 Gy to neuraxis) with primary site boost in combination with chemotherapy is being studied prospectively in adults (NCT01857453) [
         <a href="#rid59">
          59
         </a>
         ], but efficacy data are not yet available outside of the pediatric population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most, but not all, retrospective studies in adults suggest that adjuvant chemotherapy is associated with improved survival compared with craniospinal RT alone, even after adjusting for potential confounders [
         <a href="#rid60">
          60-64
         </a>
         ]. However, the added value of chemotherapy in average-risk adults is less clear than in children, both because the toxicity of chemotherapy is considerably higher in adults and because there is less urgency to reduce the total radiation dose in the mature versus developing nervous system. The typical chemotherapy regimen used in adults is the Packer regimen, which is a combination of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         [
         <a href="#rid44">
          44,57
         </a>
         ]. Weekly vincristine during RT has not been shown to improve outcomes in children, and therefore, it is not routinely given in adults [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When multiagent chemotherapy regimens are used along with RT in adults, dose modifications are required in nearly all patients, and older patients are at higher risk for toxicity and treatment-related morbidities. In a prospective single-arm trial (NOA-07) of craniospinal RT with concurrent
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         followed by up to eight cycles of chemotherapy (
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         , and vincristine), treatment was terminated or dose reduced due to toxicity in nearly 60 percent of patients by cycle four [
         <a href="#rid65">
          65
         </a>
         ]. Patients &gt;45 years of age were at increased risk for toxicity. Three-year progression-free and overall survival were 67 and 70 percent, respectively. With long-term follow-up, verbal working memory declined but health-related quality of life improved from the posttreatment baseline [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a separate prospective observational multicenter study that included 70 adults (≥21 years old) with nonmetastatic medulloblastoma, treatment consisted of maximal safe resection and craniospinal RT with posterior fossa boost in all patients [
         <a href="#rid67">
          67
         </a>
         ]. Forty-nine out of 70 patients also received weekly
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         during RT followed by up to eight cycles of maintenance chemotherapy (
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         , vincristine). With a median follow-up of 44 months, the four-year event-free and overall survival rates were 68 and 89 percent, respectively. In a multivariable analysis, factors associated with worse outcome included presence of residual tumor after surgery and lateral tumor location. Receiving chemotherapy did not impact survival, although treatment allocation was not randomized; chemotherapy was the recommended approach in all patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-risk adults
         </strong>
         – For adults with high-risk disease, including those with positive lumbar CSF cytology, we suggest standard-dose craniospinal RT with primary site boost followed by multiagent maintenance chemotherapy. The addition of preradiation or concurrent chemotherapy during RT is also considered in younger, fit patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Supportive evidence for treatment in high-risk adults includes a prospective phase II trial of 26 patients with T3b-T4 tumors, metastatic disease (either on brain and spine MRI or lumbar CSF cytology), or postoperative residual tumor (&gt;1.5 cm
         <sup>
          2
         </sup>
         ) [
         <a href="#rid68">
          68
         </a>
         ]. Patients were treated with two cycles of upfront chemotherapy (mainly
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) followed by craniospinal RT and adjuvant chemotherapy. With a median follow-up of 7.6 years, 5-year overall survival was 73 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrent disease
         </strong>
         – Treatment of recurrent disease should be individualized, and there are no standard regimens. Re-resection may be beneficial for a localized brain recurrence, followed by either additional chemotherapy or focal RT. High-dose chemotherapy with autologous HCT rescue can be considered in patients who achieve a complete response with conventional chemotherapy or who have no residual disease after resection [
         <a href="#rid57">
          57,69
         </a>
         ]. Limited data support the use of
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         in recurrent SHH pathway tumors [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="local">
          'Recurrent disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1128059">
         <span class="h1">
          POST-THERAPY SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following completion of therapy and restaging, patients are seen at periodic intervals to monitor for treatment complications and disease recurrence. Our approach is to see patients every three months for the first one to two years, then every 6 to 12 months for the next 5 to 10 years, then every one to two years or as clinically indicated. At these visits, we perform a history and physical examination and obtain brain MRI to monitor for recurrence, as well as spine MRI in patients with previous spine disease and as clinically indicated.
        </p>
        <p>
        </p>
        <p>
         The utility of routine screening spine MRIs is likely to be low in patients without a history of disseminated disease. In an observational study that included 89 patients with medulloblastoma followed with screening brain and spine MRIs, 990 brain MRIs and 758 spine MRIs were obtained over a median follow-up of 52 months [
         <a href="#rid71">
          71
         </a>
         ]. An isolated spine recurrence was detected on five spine MRIs, with a detection rate of 7/1000 (0.7 percent).
        </p>
        <p class="headingAnchor" id="H3177355">
         <span class="h1">
          RECURRENT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the improved prognosis for children with medulloblastoma, an estimated 20 to 30 percent will relapse following their initial treatment [
         <a href="#rid72">
          72
         </a>
         ]. Relapses tend to be local in approximately one-third of patients, disseminated (brain or spine) in one-third, and both local and disseminated in the remaining third [
         <a href="#rid9">
          9,44,73
         </a>
         ]. In children, most relapses occur within the first three years after diagnosis; in adults, late relapses appear to be more common, as are extraneural metastases, typically to bone or bone marrow, which is rarely seen in the pediatric population in the modern era [
         <a href="#rid67">
          67,74
         </a>
         ].
        </p>
        <p>
         The likelihood of long-term survival decreases substantially in the setting of recurrent disease after initial therapy. High-dose chemotherapy with autologous hematopoietic cell transplantation (HCT; rescue) has been studied by multiple groups in this setting [
         <a href="#rid69">
          69,72,75-77
         </a>
         ]. In small series, this approach has resulted in prolonged disease-free survival in approximately 20 to 25 percent of patients that had
         <strong>
          not
         </strong>
         received prior irradiation [
         <a href="#rid69">
          69,72
         </a>
         ]. High-dose chemotherapy with HCT is not effective in patients who have received prior radiation therapy (RT).
        </p>
        <p>
         For infants and young children who relapse following surgery and chemotherapy alone, salvage therapy with craniospinal radiation can sometimes result in prolonged disease-free survival [
         <a href="#rid78">
          78
         </a>
         ]. A multicenter retrospective study identified 380 patients with progressive or relapsed medulloblastoma after initial therapy that did not include craniospinal radiation, all less than six years of age at the time of initial diagnosis [
         <a href="#rid79">
          79
         </a>
         ]. Treatment included craniospinal radiation and systemic chemotherapy in most patients. Among 294 patients treated with curative intent, three- and five-year postrelapse survival rates were 52 and 43 percent, respectively. On multivariable analysis in 150 patients for whom molecular subgrouping was available, factors associated with improved survival included localized relapse, sonic hedgehog (SHH) subgroup, treatment with craniospinal radiation, and age ≥36 months at initial diagnosis.
        </p>
        <p class="headingAnchor" id="H660046">
         <span class="h1">
          EMERGING THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhibition of molecular targets involved in the pathogenesis of medulloblastoma is an area of active investigation, particularly for the sonic hedgehog (SHH) pathway tumors [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         Smoothened (SMO) inhibitors such as
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         , which has been approved by the US Food and Drug Administration (FDA) for treatment of advanced basal cell carcinoma, have shown evidence of activity in some, but not all, SHH medulloblastomas [
         <a href="#rid81">
          81,82
         </a>
         ]. There are ongoing efforts to understand mechanisms of acquired resistance and molecular predictors of response within the SHH group, which is genetically heterogeneous [
         <a href="#rid83">
          83,84
         </a>
         ]. Trials thus far have been mixed.
        </p>
        <p>
         In two phase II trials by the Pediatric Brain Tumor Consortium, 31 adults and 12 pediatric patients with recurrent medulloblastoma were treated with
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         150 to 300 mg per day [
         <a href="#rid70">
          70
         </a>
         ]. There were no responses observed in the 31 patients with non-SHH pathway tumors. Among the 12 patients with SHH tumors, four had a protocol-defined response (complete or partial response maintained for at least eight weeks). Responders to vismodegib were more likely to harbor patched 1 (
         <em>
          PTCH1
         </em>
         ) mutations and/or loss of heterozygosity, while nonresponders were enriched in downstream molecular alterations such as
         <em>
          SUFU
         </em>
         and
         <em>
          GLI2
         </em>
         . Diffuse p53 staining, as seen in
         <em>
          TP53
         </em>
         -mutant SHH tumors, was also predictive of nonresponse to SMO inhibition. A separate phase I/II trial of
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         with or without vismodegib in 24 patients with recurrent medulloblastoma established safety of the combination but did not show an overall benefit in progression-free survival [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3179483">
         <span class="h1">
          PROGNOSIS AND GENETIC RISK
         </span>
         <span class="headingEndMark">
          —
         </span>
         With modern multimodality therapy, approximately 75 percent of all children diagnosed with medulloblastoma will survive into adulthood. Clinical and histologic factors that are associated with worse prognosis include young age (less than three years), disseminated or metastatic disease at the time of diagnosis, residual disease after resection (&gt;1.5 cm
         <sup>
          2
         </sup>
         ), large cell and anaplastic histology, and
         <em>
          MYC
         </em>
         amplification.
        </p>
        <p>
         The prognosis of children with medulloblastoma is also influenced by genetic risk. The incidence of germline mutations causing genetic predisposition to cancer is significantly higher than previously thought, ranging 5 to 6 percent overall and as high as 20 percent for patients in the SHH subgroup  (
         <a class="graphic graphic_table graphicRef118357" href="/z/d/graphic/118357.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid86">
          86
         </a>
         ]. Testing for germline mutations is now recommended, especially for subgroups with highest risk or if the family history is consistent with increased risk of cancer. Identification of genetic risk is critical not only for appropriate genetic counseling of the patient and relatives, but also for appropriate surveillance of other cancers for which the genetic predisposition causes increased risk. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Genetic predisposition'
         </a>
         .)
        </p>
        <p>
         The prognosis of patients with genetic predisposition is variable by specific mutation but overall appears to be worse, with 52 percent five-year progression-free survival (95% CI 40-69) and 65 percent overall survival (95% CI 52-81) in these patients [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children ≥3 years
         </strong>
         – Prognostic groups have been refined through molecular stratification, as illustrated by the SJMB03 prospective trial of risk-adapted therapy in 330 children ages 3 to 21 years with newly diagnosed medulloblastoma [
         <a href="#rid41">
          41
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sonic hedgehog (SHH) tumors
         </strong>
         – Among SHH tumors, two divergent prognostic groups emerged. A low-risk subset had a very favorable prognosis with standard therapy, with a five-year progression-free survival of 100 percent. This group was identified by absence of all of the following: metastatic disease,
         <em>
          TP53
         </em>
         mutation, LC/A histology,
         <em>
          MYC
         </em>
         amplification,
         <em>
          GL12
         </em>
         mutation, and chromosome 17p loss. In the presence of any of these factors, prognosis was much worse (five-year progression-free survival &lt;50 percent) [
         <a href="#rid41">
          41
         </a>
         ]. Patients with SHH tumors have been shown to have particularly high risk of germline mutations, most commonly
         <em>
          SUFU
         </em>
         ,
         <em>
          PTCH1
         </em>
         ,
         <em>
          TP53
         </em>
         , partner and localizer of BRCA2 (
         <em>
          PALB2
         </em>
         ), and
         <em>
          BRCA2
         </em>
         [
         <a href="#rid86">
          86
         </a>
         ]. Germline mutations of
         <em>
          TP53
         </em>
         are associated with a remarkably poor prognosis in SHH medulloblastoma. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Li-Fraumeni syndrome (TP53)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Wingless-related integration site (Wnt) tumors
         </strong>
         – All 53 children with Wnt pathway tumors were alive and progression free at five years. There were four late deaths in this group related to second malignancies or pulmonary fibrosis [
         <a href="#rid41">
          41
         </a>
         ]. Going forward, clinical trials are investigating reducing therapy in this group. Children with Wnt tumors without somatic mutation of catenin beta 1 (
         <em>
          CTNNB1
         </em>
         )
         <em>
         </em>
         have high risk of germline adenomatous polyposis coli (
         <em>
          APC
         </em>
         )
         <em>
         </em>
         mutations [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Familial adenomatous polyposis (APC)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Group 3 and 4 tumors
         </strong>
         – These tumors had overlapping biology and were analyzed based on a variety of molecular assays. Three risk groups emerged with integration of methylation analysis. The main risk factors for poor outcome were
         <em>
          MYC
         </em>
         amplification and metastatic disease at diagnosis; with either of these factors, five-year progression-free survival was approximately 50 percent [
         <a href="#rid41">
          41
         </a>
         ]. Patients with group 3 and 4 tumors have increased risk of germline
         <em>
          PALB2
         </em>
         and
         <em>
          BRCA2
         </em>
         mutations [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Other germline mutations (BRCA2, PALB2, GPR161)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants and children &lt;3 years
         </strong>
         – Children younger than age three years have a poor prognosis, with an estimated five-year survival of approximately 40 to 50 percent [
         <a href="#rid32">
          32,34
         </a>
         ]. This is in part due to the necessary reduction or elimination of radiation. Young children with disseminated disease at the time of diagnosis have a particularly poor prognosis, with a five-year survival of approximately 15 to 30 percent [
         <a href="#rid32">
          32,34
         </a>
         ]. Germline
         <em>
          SUFU
         </em>
         or
         <em>
          PTCH1
         </em>
         mutations occur most frequently in infants, with a median age at diagnosis of two years [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Nevoid basal cell carcinoma syndrome (PTCH1, SUFU)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – Adults with medulloblastoma have a worse prognosis compared with children, with long-term survival ranging from approximately 50 to 80 percent in most studies [
         <a href="#rid87">
          87-92
         </a>
         ]. Survival may be improving with contemporary multimodality treatment, however [
         <a href="#rid91">
          91
         </a>
         ]. Clinical risk factors for worse outcomes include older age (eg, &gt;30 years), incomplete resection, and disseminated disease. Extracranial relapse and late recurrences (beyond five years) are uncommon but well described [
         <a href="#rid91">
          91
         </a>
         ]. Group 4 tumors have a particularly poor prognosis in adults, with a high incidence of high-risk disease and large cell and/or anaplastic histology [
         <a href="#rid93">
          93
         </a>
         ]. Adults carry the greatest risk for
         <em>
          PALB2
         </em>
         and
         <em>
          BRCA2
         </em>
         germline mutations [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Other germline mutations (BRCA2, PALB2, GPR161)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3177362">
         <span class="h1">
          COMPLICATIONS OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Each component of treatment can cause delayed complications that have a profound effect on quality of life and longevity in medulloblastoma survivors, particularly those patients diagnosed and treated during childhood and adolescence [
         <a href="#rid94">
          94,95
         </a>
         ]. Although the late effects of treatment on quality of life are often attributed to craniospinal radiation therapy (RT), chemotherapy has a significant role in aggravating the adverse effects of RT [
         <a href="#rid9">
          9,96
         </a>
         ].
        </p>
        <p>
         Specific long-term follow-up
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=88801" target="_blank">
          survivorship guidelines
         </a>
         for childhood central nervous system (CNS) tumors have been published by the Children's Oncology Group (COG) and are available online [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3177369">
         <span class="h2">
          Posterior fossa syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Posterior fossa syndrome, also called cerebellar cognitive affective syndrome or cerebellar mutism, can be seen in approximately one-quarter of patients [
         <a href="#rid98">
          98
         </a>
         ]. It is a distinctive postoperative complication that is caused by injury to the inferior cerebellar vermis and cerebellar outflow pathways. Symptoms may largely be caused by disrupted communication between the cerebellum and mediodorsal thalamus.
        </p>
        <p>
         This complication is characterized by impaired language production in association with emotional lability [
         <a href="#rid99">
          99-101
         </a>
         ]. The most severely affected individuals also have varying degrees of inattention or difficulty initiating movement. Other associated postoperative neurologic symptoms include cranial nerve palsies or bowel and bladder incontinence [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         Posterior fossa syndrome can appear one to two days after surgery. Symptoms frequently improve over the course of weeks to months, although some patients may not fully recover language skills for months or years. In a prospective study of 450 children from the COG study, 24 percent had symptoms consistent with posterior fossa syndrome, and 92 percent of these were moderately to severely affected [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         Patients with medulloblastoma with associated posterior fossa syndrome are also at increased risk of long-term neurocognitive dysfunction. In a prospective study with five years of follow-up, patients with posterior fossa syndrome had worse neurocognitive function compared with age- and treatment-matched controls at all time points [
         <a href="#rid104">
          104
         </a>
         ]. Mean scores were consistently lower than controls on measures of intellectual ability, processing speed, and attention; some functions, including attention and working memory, declined over time.
        </p>
        <p class="headingAnchor" id="H3177376">
         <span class="h2">
          Neurocognitive impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurocognitive impairment is commonly observed following multimodality treatment for medulloblastoma, particularly in young children; this can be severe. Adult survivors of childhood medulloblastoma are half as likely as their unaffected siblings to earn a college degree [
         <a href="#rid105">
          105
         </a>
         ]. Risk factors for increased severity of long-term deficits include younger age, high-risk disease, and radiation dose [
         <a href="#rid95">
          95,106
         </a>
         ].
        </p>
        <p>
         Late toxicity is particularly prominent in young children [
         <a href="#rid107">
          107-110
         </a>
         ]. The most commonly observed deficits are in process speed, attention, and working memory [
         <a href="#rid111">
          111
         </a>
         ]. Cumulative exposure to anesthesia during therapy may also be associated with increased risk for neurocognitive impairment among survivors [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
         Limited observational data suggest that proton craniospinal RT may be associated with less neurocognitive decline compared with conventional photon delivery methods [
         <a href="#rid17">
          17,18,113
         </a>
         ]. In one nonrandomized comparative study, children who received proton RT had stable scores in most domains and superior performance compared with children who received photon RT at a mean follow-up of over four years, with the exception of processing speed, which declined in both groups [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Neuropsychological examinations are recommended in all medulloblastoma survivors to assist with needs assessment and monitor for changes over time. They can be especially useful at times of transition into middle school, high school, and college to aid in curriculum planning, appropriate placement, and educational accommodations.
        </p>
        <p class="headingAnchor" id="H3177383">
         <span class="h2">
          Hearing loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ototoxicity is a significant risk given the doses of RT used in medulloblastoma protocols, and there may be synergistic toxicity between RT and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         chemotherapy. Approximately 40 to 60 percent of long-term survivors of childhood medulloblastoma experience moderate to severe hearing loss, often requiring hearing assistance devices [
         <a href="#rid12">
          12,95,105
         </a>
         ]. Use of protons and intensity-modulated RT (IMRT) techniques to reduce the dose to otic structures may be associated with lower rates of significant hearing loss, although longer-term follow-up is still needed [
         <a href="#rid12">
          12,16,114
         </a>
         ].
         <em>
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Ototoxicity'
         </a>
         .)
        </p>
        <p>
         Early detection of ototoxicity in children receiving platinum agents may minimize the risk of severe impairment in the frequencies required for speech recognition, and all children should have a baseline audiogram prior to receiving
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and irradiation so that hearing changes can be followed over time. Audiograms are typically performed every one to two years in survivors to monitor for hearing loss  (
         <a class="graphic graphic_table graphicRef120324" href="/z/d/graphic/120324.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         Intravenous
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         has been studied as a preventive agent when administered with each dose of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and was approved by the US Food and Drug Administration in September 2022 to help decrease the risk of hearing loss in children receiving cisplatin for localized, nonmetastatic solid tumors [
         <a href="#rid115">
          115
         </a>
         ]. Approval was based on data from two randomized trials, one in children with hepatoblastoma and one in children with a variety of solid tumors (26 out of 125 with medulloblastoma), showing that sodium thiosulfate reduced the relative incidence of cisplatin-induced hearing loss by approximately 40 percent [
         <a href="#rid116">
          116-118
         </a>
         ]. Although the approval of sodium thiosulfate is applicable to children with average-risk medulloblastoma, there is not yet consensus on its role, particularly in children treated with contemporary RT techniques (protons, IMRT) that spare the cochlea. Safety and efficacy have
         <strong>
          not
         </strong>
         been established in adults or in children with disseminated or metastatic disease. Supporting data on sodium thiosulfate are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">
          "Overview of neurologic complications of platinum-based chemotherapy", section on 'Ototoxicity'
         </a>
         .)
        </p>
        <p>
         Rarely, a slowly progressive sensorineural hearing loss and ataxia has been reported developing years after treatment [
         <a href="#rid119">
          119
         </a>
         ]. In some cases, this has been found to occur in association with a hypointense rim of iron coating the surface of the cerebellum and brainstem and has been called superficial siderosis [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14282028">
         <span class="h2">
          Skeletal problems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Craniospinal RT can cause decreased vertebral height and skeletal growth, resulting in significantly decreased adult height [
         <a href="#rid25">
          25
         </a>
         ]. Patients are also prone to scoliosis [
         <a href="#rid120">
          120
         </a>
         ]. The vertebral effects appear to be mediated by decreased levels of growth hormone (GH) and may be partially avoided with decreased doses of radiation [
         <a href="#rid121">
          121
         </a>
         ] or use of proton RT [
         <a href="#rid122">
          122
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5830.html" rel="external">
          "Bone problems in childhood cancer patients", section on 'Altered epiphyseal growth'
         </a>
         .)
        </p>
        <p>
         In addition, survivors are at risk for decreased bone mineral density (BMD) and vertebral fractures [
         <a href="#rid123">
          123,124
         </a>
         ]. Adequate calcium and vitamin D intake, weight-bearing exercise, and avoidance of smoking are key aspects of preventive care. Early identification and therapy of hormone deficits has the potential to preserve BMD. (See
         <a class="medical medical_review" href="/z/d/html/5830.html" rel="external">
          "Bone problems in childhood cancer patients", section on 'Reduced bone mineral density'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3177390">
         <span class="h2">
          Endocrine abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocrine abnormalities are very common following RT for medulloblastoma [
         <a href="#rid121">
          121,122,125,126
         </a>
         ]. Irradiation of the pituitary hypothalamic axis can result in GH, adrenocorticotrophic hormone (ACTH), and thyroid-stimulating hormone (TSH) deficiencies. In addition, irradiation of the thyroid can cause primary hypothyroidism. Hypogonadism and early puberty have also been described.
        </p>
        <p>
         The incidence of endocrine abnormalities was illustrated by a prospective series of 88 children treated between 1996 and 2003 at St. Jude Children's Research Hospital for embryonal brain tumors, including 78 (89 percent) with medulloblastoma [
         <a href="#rid125">
          125
         </a>
         ]. All patients underwent detailed endocrinologic evaluation and were followed for a minimum of one year. The following findings were noted at a median follow-up of 1.5 to 1.8 years:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GH deficiency was present in 94 percent. (See
         <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">
          "Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TSH deficiency was present in 10 percent overall and was more frequent in those receiving higher doses of radiation to the hypothalamus. (See
         <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">
          "Acquired hypothyroidism in childhood and adolescence", section on 'Etiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary hypothyroidism was present in 50 percent, but was less common in average-risk patients, who received lower doses of radiation (four-year incidence 13 versus 54 percent in high-risk patients who received higher doses of irradiation). (See
         <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">
          "Acquired hypothyroidism in childhood and adolescence", section on 'Other causes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ACTH deficiency was present in 43 percent. (See
         <a class="medical medical_review" href="/z/d/html/5815.html" rel="external">
          "Causes of central adrenal insufficiency in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Risk factors include young age at the start of RT, dose of RT to the hypothalamus and pituitary, and time elapsed since treatment [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
         Use of proton RT may reduce the risk of some, but not all, of these endocrine abnormalities. In a study that included 40 children with medulloblastoma treated with proton radiation and 37 children treated with photon radiation, proton radiation was associated with a reduced risk of hypothyroidism (23 versus 69 percent) and requirement for any endocrine replacement therapy (55 versus 78 percent), but no change in the incidence of GH deficiency (53 versus 57 percent), adrenal insufficiency (5 versus 8 percent), or precocious puberty (18 versus 16 percent), with a median follow-up of six to seven years [
         <a href="#rid122">
          122
         </a>
         ]. The reduced risk of hypothyroidism is driven by lower rates of primary hypothyroidism because the thyroid gland receives less radiation with proton RT; rates of central hypothyroidism are similar [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
         Due to the high rates of endocrine dysfunction in survivors of medulloblastoma, we recommend a baseline endocrine evaluation within a year of completing therapy and annual blood work to screen for hypothyroidism, GH deficiency, and adrenal insufficiency, typically under the supervision of an endocrinologist  (
         <a class="graphic graphic_table graphicRef69558" href="/z/d/graphic/69558.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">
          "Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3911863354">
         <span class="h2">
          Infertility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both craniospinal RT and chemotherapy pose risks for fertility impairment in survivors [
         <a href="#rid128">
          128,129
         </a>
         ]. Rates of impairment and recovery of fertility are not well studied in medulloblastoma survivors, however.
        </p>
        <p>
         In one study of 31 females with a history of childhood medulloblastoma, persistent primary ovarian dysfunction was present in approximately 20 percent of patients with a median age of 17 years at last follow-up [
         <a href="#rid130">
          130
         </a>
         ]. Ovarian dysfunction requiring hormone replacement therapy was most common after high-dose chemotherapy with autologous stem cell rescue.
        </p>
        <p>
         Infertility and pregnancy in cancer survivors are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4801.html" rel="external">
          "Overview of infertility and pregnancy outcome in cancer survivors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17015.html" rel="external">
          "Overview of cancer survivorship in adolescents and young adults", section on 'Fertility'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2883661871">
         <span class="h2">
          Cataracts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low-dose radiation exposure to the lens is a risk factor for premature cataracts. In one long-term follow-up study, the cumulative incidence of cataracts in medulloblastoma survivors was 14 percent at 30 years [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H372198496">
         <span class="h2">
          Cerebrovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebrovascular disease, including occlusive vascular disease and stroke, intracranial hemorrhage, and cavernous malformations, is an increasingly recognized long-term complication of cranial irradiation in brain tumor survivors. Children appear to be more susceptible to radiation-induced vasculopathy than adults, and receipt of chemotherapy along with radiation may also increase this risk. (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Cerebrovascular effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3177397">
         <span class="h2">
          Secondary neoplasms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of second neoplasms (both benign and malignant) is increased in children following RT and/or chemotherapy for primary CNS malignancies [
         <a href="#rid44">
          44,131-135
         </a>
         ]. These secondary tumors may be diagnosed many years after the original presentation. The most common secondary cancers are brain and thyroid [
         <a href="#rid94">
          94
         </a>
         ]. The cumulative incidence may be rising in the era of multimodality therapy [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         In the COG phase III study for average-risk children, secondary malignancies were diagnosed in 15 children at a median of 5.8 years after diagnosis, which translates to a cumulative 10-year incidence rate of 4.2 percent [
         <a href="#rid47">
          47
         </a>
         ]. Tumors included seven primary CNS tumors (six malignant gliomas, one pilocytic astrocytoma), three hematologic malignancies, one basal cell carcinoma in a patient with Gorlin syndrome, and four non-CNS solid tumors.
        </p>
        <p>
         Meningiomas are also common late-occurring tumors. In a study that tracked both benign and malignant second neoplasms among nearly 1000 medulloblastoma survivors, the cumulative incidence of second neoplasms was 9.5 percent, including 24 benign meningiomas (one-quarter of all tumors) and eight malignant gliomas [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         Our practice is to perform annual physical and dermatologic examinations to monitor for basal cell carcinomas and annual or every-other-year brain MRI to screen for secondary CNS tumors in medulloblastoma survivors.
        </p>
        <p class="headingAnchor" id="H1172064723">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">
          "Society guideline links: Primary brain tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3179491">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of clinical trials
         </strong>
         – Advances in molecular classification of medulloblastomas have brought significant changes in risk stratification and treatment, which are starting to be incorporated into prospective clinical trials. It is strongly recommended that all children be treated on a clinical trial that takes advantage of these important developments. Screening and testing for genetic cancer risk from germline mutations are strongly recommended. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma", section on 'Genetic counseling and testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical resection
         </strong>
         – Maximal safe resection is a key component of the treatment of all patients with medulloblastoma. Resection confirms the diagnosis, relieves increased intracranial pressure, assists in local control, and has prognostic value depending on the extent of resection. (See
         <a class="local">
          'Surgery'
         </a>
         above and
         <a class="local">
          'Increased intracranial pressure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk stratification
         </strong>
         – Following resection, treatment recommendations are based on age at diagnosis, amount of residual disease, histology, and extent of disease (metastatic versus localized). Molecular group informs prognosis and is being integrated into ongoing and future prospective clinical trials to inform escalation and deescalation of therapy. (See
         <a class="local">
          'Risk stratification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Average risk
         </strong>
         – Average risk refers to patients with complete or near-complete resection (&lt;1.5 cm
         <sup>
          2
         </sup>
         of residual tumor), negative lumbar cerebrospinal fluid (CSF) cytology, no evidence of distant metastases, and classic or nodular desmoplastic histology.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk
         </strong>
         – High risk refers to patients with ≥1.5 cm
         <sup>
          2
         </sup>
         of residual tumor after surgery, evidence of disseminated or metastatic disease, or large cell and/or anaplastic histology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative therapy
         </strong>
         –
         <strong>
         </strong>
         Most often, children with medulloblastoma are treated as part of a multicenter clinical trial or institution-specific protocol. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=88801" target="_blank">
          ClinicalTrials.gov
         </a>
         database maintained by the United States National Library of Medicine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When clinical trial enrollment is not possible, treatment is informed by ongoing and completed Children's Oncology Group (COG) trials  (
         <a class="graphic graphic_algorithm graphicRef129367" href="/z/d/graphic/129367.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Age &lt;3 years
         </strong>
         – For children &lt;3 years of age, who are at high risk of severe neurologic impairment from craniospinal radiation therapy (RT), we recommend combination chemotherapy, often paired with autologous hematopoietic stem cell rescue, in an effort to delay or avoid use of craniospinal RT (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Clinical trials in this age group are now stratifying and adapting regimens based on molecular subgroup. (See
         <a class="local">
          'Infants and young children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Average risk, age 3 to 21 years
         </strong>
         – For children 3 to 21 years of age with average-risk disease, we recommend craniospinal plus primary site RT, followed by adjuvant combination chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Single-modality therapy results in lower rates of cure. (See
         <a class="local">
          'Average-risk disease in children ≥3 years of age'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The standard dose of craniospinal RT for this group is 23.4 Gy. The primary site is boosted with 30.6 Gy, targeting the tumor bed plus a margin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For adjuvant chemotherapy, we use alternating regimens of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         /
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         /
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         /vincristine as per the COG ACNS0331 trial. Most practitioners no longer use weekly vincristine during craniospinal RT.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk, age 3 to 21 years
         </strong>
         – For most children 3 to 21 years with high-risk disease, we suggest craniospinal RT (36 Gy) plus primary site RT (18 Gy)
         <strong>
          without
         </strong>
         concurrent
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         or
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         , followed by combination chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The use of concurrent chemotherapy during RT adds toxicity but does not improve outcomes. (See
         <a class="local">
          'High-risk disease in children ≥3 years of age'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Age &gt;21 years
         </strong>
         – For most adults with medulloblastoma  (
         <a class="graphic graphic_algorithm graphicRef129366" href="/z/d/graphic/129366.html" rel="external">
          algorithm 2
         </a>
         ), we suggest craniospinal plus primary site RT followed by adjuvant combination chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For adults with poor performance status or multiple comorbidities, craniospinal RT alone, without adjuvant chemotherapy, is a reasonable alternative. Pre-RT chemotherapy may be considered for adults with high-risk disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications of therapy
         </strong>
         – Delayed complications of treatment can have a profound effect on quality of life in medulloblastoma survivors. The most common long-term complications are neurocognitive impairment, hearing loss, infertility, endocrine abnormalities, cerebrovascular disease, and second malignancies. (See
         <a class="local">
          'Complications of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3119630515">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Scott L Pomeroy, MD, PhD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Raimondi AJ, Tomita T. Medulloblastoma in childhood. Acta Neurochir (Wien) 1979; 50:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park TS, Hoffman HJ, Hendrick EB, et al. Medulloblastoma: Clinical presentation and management. Experience at the hospital for sick children, Toronto, 1950-1980. J Neurosurg 1983; 58:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry MP, Jenkin RD, Keen CW, et al. Radiation treatment for medulloblastoma. A 21-year review. J Neurosurg 1981; 55:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes EN, Shillito J, Sallan SE, et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 1988; 61:1992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Charco JO, Bolek TW, McCollough WM, et al. Medulloblastoma: Time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 1998; 42:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: A retrospective integrated clinical and molecular analysis. Lancet Oncol 2016; 17:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson EM, Bramall A, Herndon JE 2nd, et al. The clinical importance of medulloblastoma extent of resection: A systematic review. J Neurooncol 2018; 139:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarbell NJ, Loeffler JS, Silver B, et al. The change in patterns of relapse in medulloblastoma. Cancer 1991; 68:1600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 2003; 21:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004; 58:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuh GE, Loredo LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: Using proton beams to treat medulloblastoma in young children. Cancer J 2004; 10:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: Early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002; 52:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moeller BJ, Chintagumpala M, Philip JJ, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol 2011; 6:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 2013; 86:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaton BR, Esiashvili N, Kim S, et al. Clinical outcomes among children with standard-risk medulloblastoma treated with proton and photon radiation therapy: A comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys 2016; 94:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: A phase 2 single-arm study. Lancet Oncol 2016; 17:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahalley LS, Ris MD, Grosshans DR, et al. Comparing intelligence quotient change after treatment with proton versus photon radiation therapy for pediatric brain tumors. J Clin Oncol 2016; 34:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahalley LS, Peterson R, Ris MD, et al. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol 2020; 38:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baliga S, Gallotto S, Bajaj B, et al. Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy. Neuro Oncol 2022; 24:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukunaga-Johnson N, Lee JH, Sandler HM, et al. Patterns of failure following treatment for medulloblastoma: Is it necessary to treat the entire posterior fossa? Int J Radiat Oncol Biol Phys 1998; 42:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolden SL, Dunkel IJ, Souweidane MM, et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 2003; 21:3079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michalski JM, Janss AJ, Vezina LG, et al. Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J Clin Oncol 2021; 39:2685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayana A, Jeswani S, Paulino AC. The cranial-spinal junction in medulloblastoma: Does it matter? Int J Radiat Oncol Biol Phys 1999; 44:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000; 18:3004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldwein JW, Radcliffe J, Johnson J, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996; 34:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ris MD, Packer R, Goldwein J, et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol 2001; 19:3470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas JG, Barker JL, Ellenbogen RG, Geyer JR. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: Efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 2004; 58:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993; 328:1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kretschmar CS, Tarbell NJ, Kupsky W, et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: A preliminary report. J Neurosurg 1989; 71:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 1999; 17:3720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: An SFOP prospective trial in young children. Lancet Oncol 2005; 6:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998; 16:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 2005; 23:7621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mynarek M, von Hoff K, Pietsch T, et al. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. J Clin Oncol 2020; 38:2028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson GW, Rudneva VA, Buchhalter I, et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): Therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 2018; 19:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafay-Cousin L, Bouffet E, Strother D, et al. Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). J Clin Oncol 2020; 38:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson GW, Gajjar A. Genomics Paves the Way for Better Infant Medulloblastoma Therapy. J Clin Oncol 2020; 38:2010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhall G, O'Neil SH, Ji L, et al. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial. Neuro Oncol 2020; 22:1862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo KK, Margol AS, Kennedy RJ, et al. Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. J Neurooncol 2019; 145:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajjar A, Robinson GW, Smith KS, et al. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol 2021; 39:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kann BH, Park HS, Lester-Coll NH, et al. Postoperative radiotherapy patterns of care and survival implications for medulloblastoma in young children. JAMA Oncol 2016; 2:1574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta T, Pervez S, Dasgupta A, et al. Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure. Clin Cancer Res 2022; 28:4180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kortmann RD, Kühl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000; 46:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kühl J, Müller HL, Berthold F, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: Results of the German pilot trial HIT'88/'89. Klin Padiatr 1998; 210:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packer RJ, Zhou T, Holmes E, et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: Results of Children's Oncology Group trial A9961. Neuro Oncol 2013; 15:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nageswara Rao AA, Wallace DJ, Billups C, et al. Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: Report from the Children's Oncology Group. Pediatr Blood Cancer 2014; 61:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson PL, Murasko KM, Packer RJ, et al. Prospective study of the cerebellar mutism syndrome after posterior fossa surgery in two large cohorts of medulloblastoma. Ann Neurol 2002; 52:S115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakacki RI, Burger PC, Zhou T, et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: A Children's Oncology Group Phase I/II study. J Clin Oncol 2012; 30:2648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Bueren AO, Kortmann RD, von Hoff K, et al. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol 2016; 34:4151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esbenshade AJ, Kocak M, Hershon L, et al. A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leary SES, Packer RJ, Li Y, et al. Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group. JAMA Oncol 2021; 7:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung KW, Lim DH, Son MH, et al. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma. Neuro Oncol 2013; 15:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009; 27:566.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) guidelines. https://www.nccn.org/professionals/physician_gls/default.aspx#cns (Accessed on August 28, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franceschi E, Hofer S, Brandes AA, et al. EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol 2019; 20:e715.
          </a>
         </li>
         <li class="breakAll">
          U.S. National Library of Medicine. https://www.clinicaltrials.gov/ct2/show/NCT01857453?term=NCT01857453&amp;draw=2&amp;rank=1 (Accessed on July 27, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kann BH, Lester-Coll NH, Park HS, et al. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro Oncol 2017; 19:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padovani L, Sunyach MP, Perol D, et al. Common strategy for adult and pediatric medulloblastoma: A multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 2007; 68:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franceschi E, Bartolotti M, Paccapelo A, et al. Adjuvant chemotherapy in adult medulloblastoma: Is it an option for average-risk patients? J Neurooncol 2016; 128:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandes AA, Franceschi E, Tosoni A, et al. Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: A large prospective phase II trial (abstract #2003). J Clin Oncol 2010; 28:182s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocakaya S, Beier CP, Beier D. Chemotherapy increases long-term survival in patients with adult medulloblastoma--A literature-based meta-analysis. Neuro Oncol 2016; 18:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beier D, Proescholdt M, Reinert C, et al. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol 2018; 20:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dirven L, Luerding R, Beier D, et al. Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. J Neurooncol 2020; 148:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedrich C, von Bueren AO, von Hoff K, et al. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study. Eur J Cancer 2013; 49:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandes AA, Franceschi E, Tosoni A, et al. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer 2007; 110:2035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunkel IJ, Gardner SL, Garvin JH Jr, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro Oncol 2010; 12:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: Results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol 2015; 33:2646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perreault S, Lober RM, Carret AS, et al. Surveillance imaging in children with malignant CNS tumors: Low yield of spine MRI. J Neurooncol 2014; 116:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadota RP, Mahoney DH, Doyle J, et al. Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer 2008; 51:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi RV, Giantsoudi D, Raiford M, et al. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. Int J Radiat Oncol Biol Phys 2014; 88:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: Prognostic factors and patterns of relapse. Neurosurgery 2000; 47:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham ML, Herndon JE 2nd, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridola V, Grill J, Doz F, et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007; 110:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gururangan S, Krauser J, Watral MA, et al. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol 2008; 10:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller K, Mynarek M, Zwiener I, et al. Postponed is not canceled: Role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--An experience from the HIT-REZ 1997 &amp; 2005 studies. Int J Radiat Oncol Biol Phys 2014; 88:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erker C, Mynarek M, Bailey S, et al. Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. J Clin Oncol 2023; 41:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajjar AJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol 2014; 11:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A pediatric brain tumor consortium study. Clin Cancer Res 2013; 19:6305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metcalfe C, de Sauvage FJ. Hedgehog fights back: Mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011; 71:5057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ransohoff KJ, Sarin KY, Tang JY. Smoothened inhibitors in sonic hedgehog subgroup medulloblastoma. J Clin Oncol 2015; 33:2692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frappaz D, Barritault M, Montané L, et al. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. Neuro Oncol 2021; 23:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018; 19:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majd NK, Mastall M, Lin H, et al. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv 2021; 3:vdab079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buglione M, Ghirardelli P, Triggiani L, et al. Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. Rep Pract Oncol Radiother 2015; 20:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinones MC, Bélanger K, Lemieux Blanchard É, et al. Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience. Curr Oncol 2021; 28:3104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu IC, Holtzman AL, Rotondo RL, et al. Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes. J Neurooncol 2021; 153:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraf A, Yock TI, Niemierko A, et al. Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience. Neuro Oncol 2022; 24:2180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neth BJ, Raghunathan A, Kizilbash SH, et al. Management and Long-term Outcomes of Adults With Medulloblastoma: A Single-Center Experience. Neurology 2023; 101:e1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao F, Ohgaki H, Xu L, et al. Molecular subgroups of adult medulloblastoma: A long-term single-institution study. Neuro Oncol 2016; 18:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ning MS, Perkins SM, Dewees T, Shinohara ET. Evidence of high mortality in long term survivors of childhood medulloblastoma. J Neurooncol 2015; 122:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salloum R, Chen Y, Yasui Y, et al. Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: A report from the Childhood Cancer Survivor Study. J Clin Oncol 2019; 37:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bull KS, Spoudeas HA, Yadegarfar G, et al. Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: A follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). J Clin Oncol 2007; 25:4239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albazron FM, Bruss J, Jones RM, et al. Pediatric postoperative cerebellar cognitive affective syndrome follows outflow pathway lesions. Neurology 2019; 93:e1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wisoff JH, Epstein FJ. Pseudobulbar palsy after posterior fossa operation in children. Neurosurgery 1984; 15:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rekate HL, Grubb RL, Aram DM, et al. Muteness of cerebellar origin. Arch Neurol 1985; 42:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen G, Messing-Jünger AM, Engelbrecht V, et al. Cerebellar mutism syndrome. Klin Padiatr 1998; 210:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siffert J, Poussaint TY, Goumnerova LC, et al. Neurological dysfunction associated with postoperative cerebellar mutism. J Neurooncol 2000; 48:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: A prospective study by the Children's Oncology Group. J Neurosurg 2006; 105:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreiber JE, Palmer SL, Conklin HM, et al. Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study. Neuro Oncol 2017; 19:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King AA, Seidel K, Di C, et al. Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: A report from the Childhood Cancer Survivor Study. Neuro Oncol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moxon-Emre I, Bouffet E, Taylor MD, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol 2014; 32:1760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005; 23:7152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005; 23:5511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: A Pediatric Oncology Group study. J Clin Oncol 1998; 16:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkin D, Danjoux C, Greenberg M. Subsequent quality of life for children irradiated for a brain tumor before age four years. Med Pediatr Oncol 1998; 31:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer SL, Armstrong C, Onar-Thomas A, et al. Processing speed, attention, and working memory after treatment for medulloblastoma: An international, prospective, and longitudinal study. J Clin Oncol 2013; 31:3494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacola LM, Anghelescu DL, Hall L, et al. Anesthesia Exposure during Therapy Predicts Neurocognitive Outcomes in Survivors of Childhood Medulloblastoma. J Pediatr 2020; 223:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross JP, Powell S, Zelko F, et al. Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients. Neuro Oncol 2019; 21:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vieira WA, Weltman E, Chen MJ, et al. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): A retrospective review. Radiat Oncol 2014; 9:158.
          </a>
         </li>
         <li class="breakAll">
          FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. US Food and Drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sodium-thiosulfate-reduce-risk-ototoxicity-associated-cisplatin-pediatric-patients (Accessed on September 21, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): A multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orgel E, Villaluna D, Krailo MD, et al. Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431. Lancet Oncol 2022; 23:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brock PR, Maibach R, Childs M, et al. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med 2018; 378:2376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson NE, Sheffield S, Hope JK. Superficial siderosis of the central nervous system: A late complication of cerebellar tumors. Neurology 1999; 52:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulino AC, Suzawa HS, Dreyer ZE, et al. Scoliosis in Children Treated With Photon Craniospinal Irradiation for Medulloblastoma. Int J Radiat Oncol Biol Phys 2021; 109:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu W, Janss A, Packer RJ, et al. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neuro Oncol 2004; 6:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaton BR, Esiashvili N, Kim S, et al. Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro Oncol 2016; 18:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jussila MP, Remes T, Anttonen J, et al. Late vertebral side effects in long-term survivors of irradiated childhood brain tumor. PLoS One 2018; 13:e0209193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Atteveld JE, Pluijm SMF, Ness KK, et al. Prediction of Low and Very Low Bone Mineral Density Among Adult Survivors of Childhood Cancer. J Clin Oncol 2019; 37:2217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughton SJ, Merchant TE, Sklar CA, et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 2008; 26:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vatner RE, Niemierko A, Misra M, et al. Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. J Clin Oncol 2018; 36:2854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldrich KD, Horne VE, Bielamowicz K, et al. Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma. J Neurooncol 2021; 155:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfitzer C, Chen CM, Wessel T, et al. Dynamics of fertility impairment in childhood brain tumour survivors. J Cancer Res Clin Oncol 2014; 140:1759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vern-Gross TZ, Bradley JA, Rotondo RL, Indelicato DJ. Fertility in childhood cancer survivors following cranial irradiation for primary central nervous system and skull base tumors. Radiother Oncol 2015; 117:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balachandar S, Dunkel IJ, Khakoo Y, et al. Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. Pediatr Blood Cancer 2015; 62:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A Pediatric Oncology Group study. Ann Neurol 1998; 44:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: A population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devarahally SR, Severson RK, Chuba P, et al. Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence. Pediatr Hematol Oncol 2003; 20:617.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 88801 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/517184" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Medulloblastoma in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6827349" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children, toronto, 1950-1980.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7241214" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Radiation treatment for medulloblastoma. A 21-year review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3129177" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9747832" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Medulloblastoma: time-dose relationship based on a 30-year review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26976201" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29796724" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The clinical importance of medulloblastoma extent of resection: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1893359" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The change in patterns of relapse in medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12697884" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14967427" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15701271" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11849779" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21635776" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23433794" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26700707" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26830377" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26811522" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31774710" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34788463" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9747831" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915597" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34110925" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219798" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The cranial-spinal junction in medulloblastoma: does it matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10944134" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8598368" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11481352" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15001259" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8388548" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2585072" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577843" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15758008" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16054568" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9440745" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234523" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32330099" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29778738" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31774708" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32352857" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Genomics Paves the Way for Better Infant Medulloblastoma Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32304218" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31621042" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33405951" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27491009" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35653134" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16943538" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10661332" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743957" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23099653" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23956184" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prospective study of the cerebellar mutism syndrome after posterior fossa surgery in two large cohorts of medulloblastoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22665539" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27863192" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28000417" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292305" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17012043" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23258845" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075266" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075266" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31797797" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31797797" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27540083" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Adjuvant chemotherapy and overall survival in adult medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17498567" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26940908" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: A large prospective phase II trial (abstract #2003)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26359208" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Chemotherapy increases long-term survival in patients with adult medulloblastoma--a literature-based meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29016837" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32367436" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23182688" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17823910" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Long-term results of a prospective study on the treatment of medulloblastoma in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20167818" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26169613" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24401959" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Surveillance imaging in children with malignant CNS tumors: low yield of spine MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18623206" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24521681" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10981749" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Adult medulloblastoma: prognostic factors and patterns of relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9164190" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17541945" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755919" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24661654" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997&amp;2005 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36548930" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25348790" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Medulloblastoma-translating discoveries from the bench to the bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19726761" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24077351" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21771911" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26195713" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33825892" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29753700" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34377987" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26109916" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34436037" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34105033" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35671386" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37524533" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Management and Long-term Outcomes of Adults With Medulloblastoma: A Single-Center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27106407" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25557108" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Evidence of high mortality in long term survivors of childhood medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30730781" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17878477" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15576413" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31527284" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Pediatric postoperative cerebellar cognitive affective syndrome follows outflow pathway lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6504288" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Pseudobulbar palsy after posterior fossa operation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4015467" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Muteness of cerebellar origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743960" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cerebellar mutism syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11026700" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Neurological dysfunction associated with postoperative cerebellar mutism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17184075" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29016818" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039368" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24516024" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192599" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16110011" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9586884" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9835903" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Subsequent quality of life for children irradiated for a brain tumor before age four years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23980078" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32532646" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Anesthesia Exposure during Therapy Predicts Neurocognitive Outcomes in Survivors of Childhood Medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30997512" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25041714" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25041714" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27914822" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35489339" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29924955" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9921865" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Superficial siderosis of the central nervous system: a late complication of cerebellar tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33516438" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Scoliosis in Children Treated With Photon Craniospinal Irradiation for Medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15134625" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26688075" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30562369" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Late vertebral side effects in long-term survivors of irradiated childhood brain tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31169453" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Prediction of Low and Very Low Bone Mineral Density Among Adult Survivors of Childhood Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18309946" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30118397" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34596831" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24841737" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Dynamics of fertility impairment in childhood brain tumour survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26475251" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Fertility in childhood cancer survivors following cranial irradiation for primary central nervous system and skull base tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25346052" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9749596" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11058888" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11878577" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Prognostic factors and secondary malignancies in childhood medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11309438" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14578032" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
